"Cyclin B1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin B subtype that colocalizes with MICROTUBULES during INTERPHASE and is transported into the CELL NUCLEUS at the end of the G2 PHASE.
| Descriptor ID |
D056744
|
| MeSH Number(s) |
D12.644.360.262.120.100 D12.776.167.218.120.100 D12.776.476.262.120.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cyclin B1".
Below are MeSH descriptors whose meaning is more specific than "Cyclin B1".
This graph shows the total number of publications written about "Cyclin B1" by people in this website by year, and whether "Cyclin B1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin B1" by people in Profiles.
-
Patel JR, Banjara B, Ohemeng A, Davidson AM, Bou? SM, Burow ME, Tilghman SL. Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1. Nutrients. 2023 Mar 28; 15(7).
-
Cao JY, Wang B, Tang TT, Wen Y, Li ZL, Feng ST, Wu M, Liu D, Yin D, Ma KL, Tang RN, Wu QL, Lan HY, Lv LL, Liu BC. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics. 2021; 11(11):5248-5266.
-
Castellani CM, Torres-Ocampo AP, Breffke J, White AB, Chambers JJ, Stratton MM, Maresca TJ. Live-cell FLIM-FRET using a commercially available system. Methods Cell Biol. 2020; 158:63-89.
-
Afonso O, Castellani CM, Cheeseman LP, Ferreira JG, Orr B, Ferreira LT, Chambers JJ, Morais-de-S? E, Maresca TJ, Maiato H. Spatiotemporal control of mitotic exit during anaphase by an aurora B-Cdk1 crosstalk. Elife. 2019 08 19; 8.
-
Hilliard TS, Miklossy G, Chock C, Yue P, Williams P, Turkson J. 15a-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models. Mol Cancer Ther. 2017 04; 16(4):601-613.
-
Mir H, Kapur N, Singh R, Sonpavde G, Lillard JW, Singh S. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. Cell Cycle. 2016; 15(6):819-26.
-
Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res. 2014; 2014:827827.
-
Samuel T, Fadlalla K, Mosley L, Katkoori V, Turner T, Manne U. Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. Anticancer Res. 2012 Jan; 32(1):61-71.
-
Samuel T, Fadlalla K, Turner T, Yehualaeshet TE. The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle. Nutr Cancer. 2010; 62(8):1025-35.
-
Yu H, Yao X. Cyclin B1: conductor of mitotic symphony orchestra. Cell Res. 2008 Feb; 18(2):218-20.